Legal status · Canada
Is Degarelix legal in Canada?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
Yes. Degarelix is an approved medicine in Canada, classified as "Health Canada approved, prescription only". Approval covers its labeled indication and it is supplied on prescription, not over the counter. Products labeled "research use only" fall outside that approval and the label does not make human use lawful. On the evidence, 3 human studies are cited on its profile.
Degarelix in Canada at a glance
| Classification | Health Canada approved, prescription only |
|---|---|
| Note | Approved for advanced hormone-dependent prostate cancer. Prescription only. |
| Health Canada approval status | Approved by Health Canada for its labeled use |
| Human studies cited | 3 of 3 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Degarelix profile, checked against Health Canada, Health Products and Food Branch (Health Canada) listings at the reviewed date.
What this means
- 01
Health Canada has approved Degarelix for at least one labeled indication, so a pharmaceutical-grade product exists in Canada and is dispensed on prescription.
- 02
Approval is indication-specific. Uses outside the label are a clinical decision for a prescriber, not something the approval itself authorizes.
- 03
Unlicensed online vials, including those labeled "research use only", are not the approved product and are not covered by the approval.
What Degarelix is
A GnRH antagonist approved in 2008 for advanced prostate cancer. In its 610-patient phase 3, testosterone was at or below 0.5 ng/mL by day 3 in about 96 percent of degarelix patients and in none of the leuprolide patients, and it met non-inferiority over 12 months. Injection site reactions occurred in 40 percent versus under 1 percent with intramuscular leuprolide, and the trial designed to test whether it is safer for the heart was terminated early and found no difference.
Degarelix is a synthetic decapeptide containing five D-amino acids that blocks the GnRH receptor directly instead of overstimulating it. The FDA approved it on 24 December 2008 under NDA 022201 for treatment of patients with advanced prostate cancer.
Mechanism: Direct competitive antagonism at the pituitary GnRH receptor. Blocking the receptor stops luteinising hormone and follicle-stimulating hormone release immediately, so testosterone falls within days with no initial surge.
Regulatory history: FDA-approved on 24 December 2008 under NDA 022201, marketed as Firmagon, for treatment of patients with advanced prostate cancer. No boxed warning. Not approved for localised prostate cancer management outside that indication, for any use in women, or for any use in healthy adults.
How Health Canada treats this kind of product
Authorises drugs for sale through a Notice of Compliance and Drug Identification Number. A compound that is not authorised for sale cannot lawfully be sold for human use, and personal importation of prescription drugs is limited.
The classification above is the The Longevity Archive reading of Health Canada, Health Products and Food Branch listings for Degarelix at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Degarelix in other countries
Frequently asked questions
Is Degarelix legal in Canada?
Yes. Degarelix is an approved medicine in Canada, classified as "Health Canada approved, prescription only". Approval covers its labeled indication and it is supplied on prescription, not over the counter. Products labeled "research use only" fall outside that approval and the label does not make human use lawful. On the evidence, 3 human studies are cited on its profile. Note: Approved for advanced hormone-dependent prostate cancer. Prescription only.
Can I buy Degarelix in Canada?
Only with a prescription. Degarelix is classified as "Health Canada approved, prescription only" in Canada, so it is dispensed by pharmacies against a prescription for its approved indication. Buying it from unlicensed online sellers or as a "research chemical" is outside that system and carries no regulatory protection. Note: Approved for advanced hormone-dependent prostate cancer. Prescription only.
Is Degarelix Health Canada approved?
Yes, for its labeled indication. In Canada Degarelix is classified as "Health Canada approved, prescription only". For comparison, the US FDA status is: FDA-approved on 24 December 2008 under NDA 022201, marketed as Firmagon, for treatment of patients with advanced prostate cancer. No boxed warning. Not approved for localised prostate cancer management outside that indication, for any use in women, or for any use in healthy adults.. On the evidence, 3 human studies are cited on its profile.
Related compounds in Canada
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Degarelix live on its compound profile.
Degarelix profileThis page is general information about the regulatory status of Degarelix in Canada, current as of Sep 2026. It is not legal advice, and classifications change; check Health Canada, Health Products and Food Branch directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.